一种新的双体抗体疗法显示,在罕见、难以治疗的多重骨髓瘤患者中,反应强劲、持久。 A new dual-antibody therapy showed strong, lasting responses in patients with rare, hard-to-treat multiple myeloma.

根据《新英格兰医学杂志》刊登的马约诊所研究报告,一种非现成的双重抗体免疫疗法显示,在患有超感性多细胞瘤的病人中,这种抗标准治疗的罕见和强势形式表现出深刻、持久的反应。 An off-the-shelf dual-antibody immunotherapy showed deep, lasting responses in patients with extramedullary multiple myeloma, a rare and aggressive form resistant to standard treatments, according to a Mayo Clinic study published in the New England Journal of Medicine. 治疗针对癌症细胞上的两种蛋白质,可立即得到治疗,不需要定制准备。 The therapy, which targets two proteins on cancer cells, is immediately available and does not require custom preparation. 早期结果显示,一些病人的肿瘤显著减少,长期恢复,给选择有限的病人带来了新的希望。 Early results indicate significant tumor reduction and prolonged remission in some patients, offering new hope for those with limited options. 这一办法仍然在早期试验中,可以改变对这一难以处理的分组的照顾。 The approach, still in early trials, could transform care for this difficult-to-treat subgroup.